AMENDMENTS TO THE SPECIFICATION

Please amend page 2 of the specification as follows:

Fig.3 shows diagram and DNA sequence of a chimeric sFv IgTCR (the nucleic acid sequence is set forth in SEQ ID NO: 1 and the corresponding amino acid sequence is set forth in SEQ ID NO:2. This region is labeled sFv-h-zeta), including the CD8 hinge modified-to-remove cysteines, within a retroviral vector. This example IgTCR molecule (using hMN14 antibody specific to CEA antigen, not part of this application) occupies nucleotides 2426 2428 to 3766 3756. (The vector sequences are incidental.) Equivalent versions using the antibodies MB3.6, 3D8, 4D4, 3E11 are prepared in analogous manner to create IgTCR, or other Ig-chimeric molecules.

Fig.4 shows the DNA sequence of:

A., B. leader plus VH (SEQ ID NOs: 3 and 4) and leader plus VL (SEQ ID NOs: 5 and 6) that specifies MB3.6.

C. As example, the VL and leader are joined with linker to VH to create MB3.6 sFv as shown (SEQ ID NO: 7), that is subsequently used in creating chimeric molecules. Other means of generating sFv are possible and included under this claim, as well as other means of creating antibody chimeric molecules under the intent of this invention.

D., E. leader plus VH (SEQ ID NOs:8 and 9) and leader plus VL (SEQ ID NOs:10 and 11) that

specifies 3D8 (includes C domain sequences).

F., G. leader plus VH (SEQ ID NOs:12 and 13) and leader plus VL (SEQ ID NOs:14 and 15) that specifies 4D4 (includes C domain sequences).

H., I. leader plus VH (SEQ ID NOs:16 and 17) and leader plus VL (SEQ ID NOs:18 and 19) that specifies 3E11 (includes C domain sequences).

These sequences are modified to prepare the sFv used in Fig.1 and Fig.3, and similarly for other constructs.

Please amend page 11 of the specification as follows:

Abstract of the Disclosure

This invention relates to specific antibodies against ganglioside GD3 called MB3.6 and against protein prostate specific membrane antigen (PSMA) called 3D8, 4D4 and 3E11 when prepared as chimeric molecules with signaling molecules of T cells and other effector cells, and the use thereof in the treatment of cancers expressing these antigens.